You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

  • Technology appraisal guidance
  • Reference number: TA118
  • Published:  24 January 2007
  • Last updated:  01 January 2012
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History
Download guidance (PDF)
  • Overview
  • 1 Recommendations
  • 2 Clinical need and practice
  • 3 The technologies
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Appraisal Committee members and NICE project team
  • 7 Sources of evidence considered by the Committee
  • Update information

Update information

January 2012: This guidance was partially updated by NICE technology appraisal guidance on cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy.

ISBN: 978-1-4731-7038-4


Previous page 7 Sources of evidence considered by the Committee
Back to top